Immunotherapy: 1999-2004 - 25/08/11
Reprint requests: Philip S. Norman, MD, Johns Hopkins Asthma and Allergy Center, 5501 Hopkins Bayview Circle, Baltimore MD 21224.Baltimore, MdThis activity is available for CME credit. See page 30A for important information.
Résumé |
Allergen immunotherapy continues to be used worldwide in the management of allergic rhinitis and asthma. We continue to refine our knowledge of the indications for immunotherapy, the allergens that can be used successfully, and the requirements for dosage and route of administration. Several additional allergens have been shown to be effective in controlled studies. The sublingual route of administration is safe and can be effective if the dose is large enough. Since reviews in 1998, further studies of immunologic changes after immunotherapy have confirmed that TH2 lymphocyte–mediated responses are suppressed, and TH1 responses are stimulated. Eosinophil and basophil inflammatory responses to allergen exposure are downregulated through one or both of these mechanisms. Research continues to seek improvements through allergen vaccine modifications suggested by recent immunologic discoveries. None of these is available in practice.
Le texte complet de cet article est disponible en PDF.Key words : Immunotherapy, allergen, T cells, cytokines, mast cell, basophil, CpG motif, peptide, anti-IgE
Abbreviations used : LAR, RI, SLAM, SLIT, TCR
Plan
| (Supported by a grant from GlaxoSmithKline, Research Triangle Park, NC) Series editor: Harold S. Nelson, MD |
|
| Disclosure of potential conflict of interest: P. Norman is a consultant to the Data Safety Monitoring Board, Neurocrine Technologies, Inc. |
Vol 113 - N° 6
P. 1013-1023 - juin 2004 Retour au numéro
Article précédent
- Reduced glucocorticoid receptor translocation in steroid-insensitive asthma
- Donald Y.M. Leung, Harold S. Nelson, Stanley J. Szefler, William W. Busse
- Continuing Medical Education examination: Immunotherapy: 1999-2004
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?